Experience of preventing new coronavirus infection (COVID-19) among healthcare workers


DOI: https://dx.doi.org/10.18565/therapy.2020.6.93-102

Vavilova V.P., Vavilov A.M., Perevochikova N.K., Tsarkova S.A., Pivovar O.I., Klimova I.I.

1) Kemerovo State Medical University of the Ministry of Healthcare of Russia; 2) Urals State Medical University of the Ministry of Healthcare of Russia; 3) Novokuznetsk State Institute of Advanced Medical Studies – branch of Russian Medical Academy of Continuing Professional Education of the Ministry of Healthcare of Russia
The aim of the study was to assess the prophylactic efficacy of Polyoxidonium in healthcare workers working with patients with COVID-19.
Material and methods. Main group (n=100) included medical workers who received Polyoxidonium 12 mg (tablets under the tongue) once a day for 30 days. Control group (n=50) included medical workers who did not receive preventive medications. For both groups, the number of ARVI and COVID-19 diseases was assessed over the period of taking the drug. Lysozyme activity and secretory immunoglobulin A (sIgA) content in the nasal secretion were evaluated. We used a number of medical scales for assessment of anxiety and depression.
Results. During the study it was shown that with the sublingual use of Polyoxidonium in the form of 12 mg tablets, not a single case of ARVI and COVID-19 was observed within 1 month, while in the control group, the percentage of ARVI cases was 8%, and the number of cases COVID-19 – 4%. In addition, in the group taking the drug, a significant increase in the indices of local immunity of the mucous membranes of the upper respiratory tract - lysozyme and sIgA - was shown, and the psychological state of the healthcare workers also improved.
Conclusion. Medical personnel working with patients with COVID-19 have reduced indicators of mucosal immunity, have a high level of anxiety and depression, which, when working in a highly infected environment, increases the risk of ARVI and COVID-19. The use of Polyoxidonium in medical workers led to an increase in the local immune defense of the nasopharyngeal mucosa and influenced a decrease in the incidence of SARS and COVID-19, which allows us to recommend Polyoxidonium as a means of prevention during the period of COVID-19.
Keywords: Polyoxidonium, Azoximer bromide, COVID-19, immunotherapy, prophylaxis, medical workers, immune system
Read entire article

Literature


  1. Nguyen L.H., Drew D.A., Graham M.S. et al. Risk of COVID-19 among front-line health-care workers and the general community: a prospective cohort study [published online ahead of print, 2020 Jul 30]. Lancet Public Health. 2020; S2468-2667(20)30164-X. doi: 10.1016/S2468-2667(20)30164-X.

  2. Вавилова В.П., Вавилов А.М., Черкаева А.Х. Возможности современной терапии острых респираторных вирусных инфекций у детей. Consilium Medicum. Педиатрия. 2015; 3: 62–67. [Vavilova V.P., Vavilov A.M., Cherkaeva A.Kh. The possibilities of modern treatment of acute respiratory viral infections in children. Consilium Medicum. Pediatriya. 2015; 3: 62–67 (In Russ.)].

  3. Костинов М.П. Иммунопатогенные свойства SARS-CoV-2 как основа для выбора патогенетической терапии. Иммунология. 2020; 1: 83–91. [Kostinov M.P. Immunopathogenic properties of SARS-CoV-2 as a basis for the choice of pathogenetic therapy. Immunologiya. 2020; 1: 83–91 (In Russ.)]. doi: 10.33029/0206-4952-2020-41-1-83-91.

  4. Yang Y., Koh D., Ng V. et al. Self perceived work related stress and the relation with salivary IgA and lysozyme among emergency department nurses. Occup Environ Med. 2002; 59: 836–41. doi: 10.1136/oem.59.12.836.

  5. Лусс Л.В. Роль и место иммуномодулирующей терапии в лечении инфекционно-воспалительных заболеваний, протекающих на фоне вторичной иммунной недостаточности. Медицинский совет. 2013; 11: 78–80. [Luss L.V. Role and place of immunomodulatory therapy in the treatment of infectious and infl ammatory diseases occurring against the background of secondary immune insuffi ciency. Meditsynskiy sovet. 2013; 11: 78–80 (In Russ.)].

  6. Временные клинические рекомендации Минздрава России «Лекарственная терапия острых респираторных вирусных инфекций (ОРВИ) в амбулаторной практике в период эпидемии COVID-19» от 16.04.2020. URL: https://static-0.rosminzdrav.ru/system/attachments/attaches/000/050/033/original/RESP_REC_V2.pdf?fbclid=IwAR1tuUeeSjMnRdhjtGmEmACHwIaC3TpbEGv4baOKAxjYGXoj8K54wzxNSOw (дата обращения – 09.09.2020). [Temporary clinical guidelines of the Ministry of Healthcare of Russia of 04.16.2020 «Drug therapy of acute respiratory viral infections (ARVI) in outpatient practice during the COVID-19 epidemic». URL: https://static-0.rosminzdrav.ru/system/attachments/attaches/000/050/033/original/RESP_REC_V2.pdf?fbclid=IwAR1tuUeeSjMnRdhjtGmEmACHwIaC3TpbEGv4baOKAxjYGXoj8K54wzxNSOw (date of access – 09.09.2020) (In Russ.)].

  7. Efficacy and safety of Polyoxidonium® in hospitalized patients with coronavirus disease covid-19. URL: https://clinicaltrials.gov/ct2/results?cond=&term=AZOXIMER+BROMIDE&cntry=&state=&city=&dist= (date of access – 07.09.2020).

  8. Харит С.М., Галустян А.Н. Азоксимера бромид – безопасный и эффективный препарат при лечении острых респираторных инфекций верхних дыхательных путей у детей: обзор результатов двойных слепых плацебо-контролируемых рандомизированных клинических исследований II и III фазы. Consilium Medicum. Педиатрия. 2017; 2: 55–61. [Kharit S.M., Galustyan A.N. Azoximer bromide is a safe and effective drug in the treatment of acute upper respiratory tract infections in children: a review of the results of double-blind, placebo-controlled, randomized phase II and III clinical trials. Consilium Medicum. Pediatriya. 2017; 2: 55–61 (In Russ.)].

  9. Михайленко А.А., Макаренко О.С., Самошин О.А., Сизякова Р.И. Профилактика гриппа и ОРЗ с помощью сублингвального применения полиоксидония®. Иммунология. 2005; 4: 215–17. [Mikhailenko A.A., Makarenko O.S., Samoshin O.A., Sizyakova R.I. Prevention of influenza and acute respiratory infections using sublingual administration of polyoxidonium®. Immunologiya. 2005; 4: 215–17 (In Russ.)].

  10. Скачков М.В. Безопасность и эффективность Полиоксидония для профилактики ОРЗ у длительно и часто болеющих пациентов. Русский медицинский журнал. 2008; 22: 1492–1493. [Skachkov M.V. Safety and efficacy of Polyoxidonium for the prevention of acute respiratory infections in long-term and frequently ill patients. Russky meditsinsky zhurnal. 2008; 22: 1492–1493 (In Russ).].

  11. Костинов М.П., Свитич О.А., Маркелова Е.В. Потенциальная иммунопрофилактика COVID-19 у групп высокого риска инфицирования. Временное пособие для врачей. М., 2020; с. 83. [Kostinov M.P., Svitich O.A., Markelova E.V. Potential immunoprophylaxis of COVID-19 in high-risk groups. Temporary guide for doctors. M. 2020; p.83 (In Russ.)].

  12. Матвеева Л.А. Местная защита респираторного тракта у детей. Томск. 1993; 276 c. [Matveeva, L.A. Local protection of the respiratory tract in children. Tomsk. 1993; 276 p.].

  13. Реброва О.Ю. Статистический анализ медицинских данных. Применение пакета прикладных программ STATISTICA. М.: Медиа Сфера, 2006; 305 с. ISBN 5-89084-013-4. [Rebrova O.Yu. Statistical analysis of medical data. Application of the STATISTICA software package. M.: Media Sfera. 2006; 305 p. ISBN 5-89084-013-4 (In Russ)].

  14. Keremi B., Beck A., Fabian T.K. et al. Stress and salivary glands. Curr Pharm Des. 2017; 23(27): 4057–65. doi: 10.2174/1381612823666170215110648.

  15. Gholami N., Sabzvari B.H., Razzaghi A., Salah S. Effect of stress, anxiety and depression on unstimulated salivary flow rate and xerostomia. J Dent Res Dent Clin Dent Prospects. Fall 2017; 11(4): 247–52. doi: 10.15171/joddd.2017.043.

  16. Farshidfar N., Hamedani S. Hyposalivation as a potential risk for SARS-CoV-2 infection: Inhibitory role of saliva. Oral Dis. 2020; 10.1111/odi.13375. doi: 10.1111/odi.13375.

  17. Markart P., Korfhagen T.R., Weaver T.E., Akinbi H.T. Mouse lysozyme M is important in pulmonary host defense against Klebsiella pneumoniae infection. Am J Respir Crit Care Med. 2004; 169(4): 454–58. doi:10.1164/rccm.200305-669OC.

  18. Shimada J., Moon S.K., Lee H.Y. et al. Lysozyme M deficiency leads to an increased susceptibility to Streptococcus pneumoniae-induced otitis media. BMC Infect Dis. 2008; 8: 134. doi: 10.1186/1471-2334-8-134.

  19. Караулов А.В., Горелов А.В. Применение азоксимера бромида в терапии инфекционно-воспалительных заболеваний органов дыхания у детей: метаанализ контролируемых клинических исследований. Журнал инфектологии. 2019; 4: 31–41. [Karaulov A.V., Gorelov A.V. Application of azoximer bromide in the treatment of infectious and infl ammatory diseases of the respiratory system in children: meta-analysis of controlled clinical studies. Zhurnal infektologii. 2019; 4: 31-41 (In Russ.)]. doi: 10.22625/2072-6732-2019-11-4-31-41.


About the Autors

Vera P. Vavilova, MD, professor of the Department of outpatient pediatrics, propedeutics of childhood diseases and postgraduate training of Kemerovo State Medical University of the Ministry of Healthcare of Russia. Address: 650059, Kemerovo, 22A Voroshilov Str. Tel..: +7 (3842) 73-48-56. E-mail: vavilovavр@mail.ru. ORCID: 0000-0001-8056-7274
Alexander M. Vavilov, MD, professor of the Department of propedeutics of internal diseases of Kemerovo State Medical University of the Ministry of Healthcare of Russia. Address: 650059, Kemerovo, 22A Voroshilov Str. Tel..: +7 (3842) 73-48-56. E-mail: vavilovalexandr@mail.ru. ORCID: 0000-0003-2969-0669
Nina K. Perevoschikova, MD, professor, head of the Department of outpatient pediatrics, propedeutics of childhood diseases and postgraduate training of Kemerovo State Medical University of the Ministry of Healthcare of Russia. Address: 650059, Kemerovo, 22A Voroshilov Str. Tel..: +7 (3842) 73-48-56. E-mail: nkp42@mail.ru. ORCID: 0000-0003-4844-2898
Sofia A. Tsarkova, MD, professor, head of the Department of outpatient pediatrics and pediatrics of the Faculty of advanced studies and professional retraining of Urals State Medical University of the Ministry of Healthcare of Russia. Address: 620028, Ekaterinburg, 3 Repin Str. Tel.: +7 (343) 382-74-54. E-mail: tsarkova_ugma@bk.ru. ORCID: 0000-0003-4588-5909
Olga I. Pivovar, PhD, associate professor, head of the Department of infectious diseases of Kemerovo State Medical University of the Ministry of Healthcare of Russia. Address: 650059, Kemerovo, 22A Voroshilov Str. Tel..: +7 (3842) 73-48-56. E-mail: kristi_sib@mail.ru. ORCID: 0000-0002-8552-6102
Irina I. Klimova, MD, professor of the Department of otorhinolaryngology named after prof. A.N. Zimin of Novokuznetsk State Institute of Advanced Medical Studies – branch of Russian Medical Academy of Continuing Professional Education of the Ministry of Healthcare of Russia. Address: 654005, Novokuznetsk, 5 Stroiteley Avenue. Tel.: +7 (3843) 45-48-73. E-mail: iikl@mail.ru. ORCID: 0000-0003-2363-2660


Similar Articles

Back to Content

Бионика Медиа